A micro-sterile inflammation array as an adjuvant for influenza vaccines

Nature Communications

Volumn 5, Issue , 2014, Pages

  Wang, Ji ^a   Shah, Dilip ^a   Chen, Xinyuan ^a   Anderson, R Rox ^a,b   Wu, Mei X ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD; INFLUENZA VACCINE; INTERFERON REGULATORY FACTOR 7; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; AMINOQUINOLINE DERIVATIVE; IMMUNOLOGICAL ADJUVANT; INTERFERON INDUCING AGENT; IRF7 PROTEIN, MOUSE; SQUALENE;

INFLUENZA; INHIBITOR; LESION; VACCINE;

ADAPTIVE IMMUNITY; ADJUVANT THERAPY; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIGEN PRESENTING CELL; ARTICLE; CELL DAMAGE; CELL DEATH; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RESPONSE; DRUG SAFETY; HEALING; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFLAMMATION; INOCULATION; LASER; LOW LEVEL LASER THERAPY; MICRO STERILE INFLAMMATION ARRAY; MOUSE; MUTATION; NON ABLATIVE FRACTIONAL LASER; NONHUMAN; PLASMACYTOID DENDRITIC CELL; SELF CONCEPT; SKIN; THERMAL INJURY; VACCINATION; VIRUS INFECTION; AGE; ANIMAL; BAGG ALBINO MOUSE; DENDRITIC CELL; DERMATITIS; GENETICS; IMMUNOLOGY; MALE; MUTANT MOUSE STRAIN; PATHOLOGY; PIG;

ADJUVANTS, IMMUNOLOGIC; AGE FACTORS; AMINOQUINOLINES; ANIMALS; DENDRITIC CELLS; DERMATITIS; INFLUENZA VACCINES; INTERFERON INDUCERS; INTERFERON REGULATORY FACTOR-7; LASER THERAPY; LASERS; MALE; MICE, INBRED BALB C; MICE, MUTANT STRAINS; SKIN; SQUALENE; SUS SCROFA;

EID: 84904640153     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms5447     Document Type: Article

References (47)

1. Chen, G. Y. & Nunez, G. Sterile inflammation: sensing and reacting to damage. Nat. Rev. Immunol. 10, 826 (2010).
2. Marichal, T. et al. DNA released from dying host cells mediates aluminum adjuvant activity. Nat. Med. 17, 996 (2011).
3. Kool, M. et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J. Exp. Med. 205, 869 (2008).
4. O'Hagan, D. T., Ott, G. S., De Gregorio, E. & Seubert, A. The mechanism of action of M59. Vaccine 30, 4341 (2012).
5. McKee, A. S. et al. Host DNA released in response to aluminum adjuvant enhances MHC class II-mediated antigen presentation and prolongs CD4 T-cell interactions with dendritic cells. Proc. Natl Acad. Sci. USA 110, E1122-E1131 (2013).
6. Eisenbarth, S. C., Colegio, O. R., O'Connor, W., Sutterwala, F. S. & Flavell, R. A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453, 1122 (2008).
7. Manstein, D., Herron, G. S., Sink, R. K., Tanner, H. & Anderson, R. R. Fractional photothermolysis: a new concept for cutaneous remodeling using microscopic patterns of thermal injury. Lasers Surg. Med. 34, 426 (2004).
8. Tajirian, A. L. & Goldberg, D. J. Fractional ablative laser skin resurfacing: a review. J. Cosmet. Laser Ther. 13, 262 (2011).
9. Saedi, N., Petelin, A. & Zachary, C. Fractionation: a new era in laser resurfacing. Clin. Plast. Surg. 38, 449 vii (2011).
10. Alexiades-Armenaka, M., Sarnoff, D., Gotkin, R. & Sadick, N. Multi-center clinical study and review of fractional ablative CO2 laser resurfacing for the treatment of rhytides, photoaging, scars and striae. J. Drugs Dermatol. 10, 352 (2011).
11. Chen, X. & Wu, M. X. Laser vaccine adjuvant for cutaneous immunization. Expert Rev. Vaccines 10, 1397 (2011).
12. Kenney, R. T., Frech, S. A., Muenz, L. R., Villar, C. P. & Glenn, G. M. Dose sparing with intradermal injection of influenza vaccine. N. Engl. J. Med. 351, 2295 (2004).
13. Belshe, R. B. et al. Serum antibody responses after intradermal vaccination against influenza. N. Engl. J. Med. 351, 2286 (2004).
14. Fishbein, D. B. et al. Rabies preexposure prophylaxis with human diploid cell rabies vaccine: a dose-response study. J. Infect. Dis. 156, 50 (1987).
15. Pancharoen, C. et al. Reduced-dose intradermal vaccination against hepatitis A with an aluminum-free vaccine is immunogenic and can lower costs. Clin. Infect. Dis. 41, 1537 (2005).
16. Gibson, S. J. et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell. Immunol. 218, 74 (2002).
17. Leyden, J., Stephens, T. J. & Herndon, Jr J. H. Multicenter clinical trial of a home-use nonablative fractional laser device for wrinkle reduction. J. Am. Acad. Dermatol. 67, 975 (2012).
18. Arnou, R. et al. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine 27, 7304 (2009).
19. Gupta, A. K., Cherman, A. M. & Tyring, S. K. Viral and nonviral uses of imiquimod: a review. J. Cutan. Med. Surg. 8, 338 (2004).
20. Monteiro-Riviere, N. A. & Riviere, J. in Advances in Swine in Biomedical Research (eds Tumbleson, M. E. & Schook, M. B.) 425-458 (Springer, 1996).
21. Beran, J. et al. Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial. BMC Med. 7, 13 (2009).
22. Leroux-Roels, I. et al. Seasonal influenza vaccine delivered by intradermal microinjection: a randomised controlled safety and immunogenicity trial in adults. Vaccine 26, 6614 (2008).
23. Boes, M. et al. T-cell engagement of dendritic cells rapidly rearranges MHC class II transport. Nature 418, 983 (2002).
24. Batista, F. D. & Harwood, N. E. The who, how and where of antigen presentation to B cells. Nat. Rev. Immunol. 9, 15 (2009).
25. Itano, A. A. & Jenkins, M. K. Antigen presentation to naive CD4 T cells in the lymph node. Nat. Immunol. 4, 733 (2003).
26. Vanbervliet, B. et al. The inducible CXCR3 ligands control plasmacytoid dendritic cell responsiveness to the constitutive chemokine stromal cell-derived factor 1 (SDF-1)/CXCL12. J. Exp. Med. 198, 823 (2003).
27. Drobits, B. et al. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J. Clin. Invest. 122, 575 (2012).
28. Sisirak, V. et al. CCR6/CCR10-mediated plasmacytoid dendritic cell recruitment to inflamed epithelia after instruction in lymphoid tissues. Blood 118, 5130 (2011).
29. Skrzeczynska-Moncznik, J. et al. Potential role of chemerin in recruitment of plasmacytoid dendritic cells to diseased skin. Biochem. Biophys. Res. Commun. 380, 323 (2009).
30. Kawai, T. & Akira, S. TLR signaling. Cell Death Differ. 13, 816 (2006).
31. Alvarez, D., Vollmann, E. H. & von Andrian, U. H. Mechanisms and consequences of dendritic cell migration. Immunity 29, 325 (2008).
32. Theofilopoulos, A. N., Baccala, R., Beutler, B. & Kono, D. H. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu. Rev. Immunol. 23, 307 (2005).
33. Jensen, L. E. Targeting the IL-1 family members in skin inflammation. Curr. Opin. Investig. Drugs 11, 1211 (2010).
34. Soumelis, V. et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat. Immunol. 3, 673 (2002).
35. Krug, A. et al. TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. Immunity 21, 107 (2004).
36. Gregorio, J. et al. Plasmacytoid dendritic cells sense skin injury and promote wound healing through type I interferons. J. Exp. Med. 207, 2921 (2010).
37. Petrovsky, N. & Aguilar, J. C. Vaccine adjuvants: current state and future trends. Immunol. Cell. Biol. 82, 488 (2004).
38. Chen, X. et al. A novel laser vaccine adjuvant increases the motility of antigen presenting cells. PLoS One 5, e13776 (2010).
39. Chen, X., Pravetoni, M., Bhayana, B., Pentel, P. R. & Wu, M. X. High immunogenicity of nicotine vaccines obtained by intradermal delivery with safe adjuvants. Vaccine 31, 159 (2012).
40. Cantisani, C. et al. Imiquimod 5% cream use in dermatology, side effects and recent patents. Recent Pat. Inflamm. Allergy Drug Discov. 6, 65 (2012).
41. Cumberbatch, M. & Kimber, I. Dermal tumour necrosis factor-alpha induces dendritic cell migration to draining lymph nodes, and possibly provides one stimulus for Langerhans' cell migration. Immunology 75, 257 (1992).
42. Sundquist, M. & Wick, M. J. TNF-alpha-dependent and-independent maturation of dendritic cells and recruited CD11c(int)CD11b\+ Cells during oral Salmonella infection. J. Immunol. 175, 3287 (2005).
43. Honda, K. et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434, 772 (2005).
44. Koyama, S. et al. Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes. Sci. Transl. Med. 2, 25ra24 (2010).
45. Hutchison, S. et al. Antigen depot is not required for alum adjuvanticity. FASEB J. 26, 1272 (2012).
46. Reed, S. G., Orr, M. T. & Fox, C. B. Key roles of adjuvants in modern vaccines. Nat. Med. 19, 1597 (2013).
47. Hong, D. K. et al. Cationic lipid/DNA complex-adjuvanted influenza A virus vaccination induces robust cross-protective immunity. J. Virol. 84, 12691 (2010).